Reported adverse events in girls aged 13–16 years after vaccination with the human papillomavirus (HPV)-16/18 vaccine in the Netherlands
Authors:
- H.E. de MelkerHMH.E. de Melker
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- Safety and Immunogenicity of the HPV-16/18 AS04-Adjuvanted Vaccine: A Randomized, Controlled Trial in Adolescent GirlsJournal of Adolescent Health, 2010
- Vaccination with a Human Papillomavirus (HPV)-16/18 AS04-Adjuvanted Cervical Cancer Vaccine in Korean Girls Aged 10-14 YearsJournal of Korean Medical Science, 2010
- Immunogenicity and Safety of Human Papillomavirus (HPV)-16/18 AS04-Adjuvanted Vaccine in Healthy Boys Aged 10–18 YearsJournal of Adolescent Health, 2009
- Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trialThe Lancet, 2007
- Immunization of Early Adolescent Females with Human Papillomavirus Type 16 and 18 L1 Virus-Like Particle Vaccine Containing AS04 AdjuvantJournal of Adolescent Health, 2007
- Quadrivalent Vaccine against Human Papillomavirus to Prevent Anogenital DiseasesNew England Journal of Medicine, 2007
- Safety and Persistent Immunogenicity of a Quadrivalent Human Papillomavirus Types 6, 11, 16, 18 L1 Virus-Like Particle Vaccine in Preadolescents and AdolescentsThe Pediatric Infectious Disease Journal, 2007
- Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trialThe Lancet, 2004
- Fever as an adverse event following immunization: case definition and guidelines of data collection, analysis, and presentationVaccine, 2004
- The Brighton Collaboration: addressing the need for standardized case definitions of adverse events following immunization (AEFI)Vaccine, 2002